OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The NCI-MATCH trial: lessons for precision oncology
Peter J. O’Dwyer, Robert J. Gray, Keith T. Flaherty, et al.
Nature Medicine (2023) Vol. 29, Iss. 6, pp. 1349-1357
Closed Access | Times Cited: 80
Peter J. O’Dwyer, Robert J. Gray, Keith T. Flaherty, et al.
Nature Medicine (2023) Vol. 29, Iss. 6, pp. 1349-1357
Closed Access | Times Cited: 80
Showing 26-50 of 80 citing articles:
Integrating comprehensive genomic profiling in the management of oncology patients: applications and challenges in Taiwan
Chen‐Yang Huang, Wen‐Kuan Huang, Kun-Yun Yeh, et al.
Biomedical Journal (2025), pp. 100851-100851
Open Access
Chen‐Yang Huang, Wen‐Kuan Huang, Kun-Yun Yeh, et al.
Biomedical Journal (2025), pp. 100851-100851
Open Access
Multi-omic profiling in breast cancer: utility for advancing diagnostics and clinical care
Emna El Gazzah, Scott Parker, Mariaelena Pierobon
Expert Review of Molecular Diagnostics (2025)
Closed Access
Emna El Gazzah, Scott Parker, Mariaelena Pierobon
Expert Review of Molecular Diagnostics (2025)
Closed Access
First‐Line Genomic Profiling in Previously Untreated Advanced Solid Tumors: 1‐Year Follow‐Up of the FIRST ‐Dx Study
Junichi Matsubara, Kumi Mukai, Tomohiro Kondo, et al.
Cancer Science (2025)
Open Access
Junichi Matsubara, Kumi Mukai, Tomohiro Kondo, et al.
Cancer Science (2025)
Open Access
New horizons at the interface of artificial intelligence and translational cancer research
Josephine Yates, Eliezer M. Van Allen
Cancer Cell (2025) Vol. 43, Iss. 4, pp. 708-727
Closed Access
Josephine Yates, Eliezer M. Van Allen
Cancer Cell (2025) Vol. 43, Iss. 4, pp. 708-727
Closed Access
Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras
Vivek Subbiah, Megan Othus, Jim Palma, et al.
American Society of Clinical Oncology Educational Book (2025) Vol. 45, Iss. 3
Closed Access
Vivek Subbiah, Megan Othus, Jim Palma, et al.
American Society of Clinical Oncology Educational Book (2025) Vol. 45, Iss. 3
Closed Access
HMGA1 sensitizes esophageal squamous cell carcinoma to mTOR inhibitors through the ETS1-FKBP12 axis
Jin-Rong Guo, Kai-Yue He, Jiali Yuan, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 7, pp. 2640-2657
Open Access | Times Cited: 3
Jin-Rong Guo, Kai-Yue He, Jiali Yuan, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 7, pp. 2640-2657
Open Access | Times Cited: 3
Das Verbundprojekt „Personalisierte Medizin für die Onkologie“ (PM4Onco) als Teil der Medizininformatik-Initiative (MII)
Patrick Metzger, Melanie Boerries
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz (2024) Vol. 67, Iss. 6, pp. 668-675
Open Access | Times Cited: 3
Patrick Metzger, Melanie Boerries
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz (2024) Vol. 67, Iss. 6, pp. 668-675
Open Access | Times Cited: 3
The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine
Tadayoshi Hashimoto, Yoshiaki Nakamura, Takao Fujisawa, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2243-2261
Open Access | Times Cited: 3
Tadayoshi Hashimoto, Yoshiaki Nakamura, Takao Fujisawa, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2243-2261
Open Access | Times Cited: 3
Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumors
Richard A. Hickman, Alexandra Miller, Bridget M Holle, et al.
Acta Neuropathologica Communications (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 3
Richard A. Hickman, Alexandra Miller, Bridget M Holle, et al.
Acta Neuropathologica Communications (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 3
Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer
Clara Helal, Cédric Pobel, Arnaud Bayle, et al.
European Journal of Cancer (2023) Vol. 195, pp. 113368-113368
Closed Access | Times Cited: 7
Clara Helal, Cédric Pobel, Arnaud Bayle, et al.
European Journal of Cancer (2023) Vol. 195, pp. 113368-113368
Closed Access | Times Cited: 7
Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution
Svetlana N. Aleksakhina, A.O. Ivantsov, Evgeny N. Imyanitov
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 4094-4094
Open Access | Times Cited: 2
Svetlana N. Aleksakhina, A.O. Ivantsov, Evgeny N. Imyanitov
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 4094-4094
Open Access | Times Cited: 2
Anti-MAPK Targeted Therapy for Ameloblastoma: Case Report with a Systematic Review
Anton Raemy, Laurence May, Nathalie Sala, et al.
Cancers (2024) Vol. 16, Iss. 12, pp. 2174-2174
Open Access | Times Cited: 2
Anton Raemy, Laurence May, Nathalie Sala, et al.
Cancers (2024) Vol. 16, Iss. 12, pp. 2174-2174
Open Access | Times Cited: 2
Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST working group
Alexander W. Wyatt, Saskia Litière, François‐Clément Bidard, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 22, pp. 5034-5041
Closed Access | Times Cited: 2
Alexander W. Wyatt, Saskia Litière, François‐Clément Bidard, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 22, pp. 5034-5041
Closed Access | Times Cited: 2
Leptomeningeal metastatic disease: new frontiers and future directions
Ahmad Ozair, Hannah Wilding, Debarati Bhanja, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 2
Ahmad Ozair, Hannah Wilding, Debarati Bhanja, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 2
AcSé-ESMART, a European precision cancer medicine proof-of-concept platform trial
Birgit Geoerger, Xavier Paolettí, Francisco Bautista, et al.
Nature Medicine (2023) Vol. 29, Iss. 12, pp. 2985-2987
Closed Access | Times Cited: 6
Birgit Geoerger, Xavier Paolettí, Francisco Bautista, et al.
Nature Medicine (2023) Vol. 29, Iss. 12, pp. 2985-2987
Closed Access | Times Cited: 6
Clinical Utility of Tumor Next-Generation Sequencing Panel Testing to Inform Treatment Decisions for Patients With Advanced Solid Tumors in a Tertiary Care Center
Lucia Bogdan, Ramy Saleh, Lisa Avery, et al.
JCO Precision Oncology (2024), Iss. 8
Open Access | Times Cited: 1
Lucia Bogdan, Ramy Saleh, Lisa Avery, et al.
JCO Precision Oncology (2024), Iss. 8
Open Access | Times Cited: 1
Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer
Ahmed Elhariri, Jaydeepbhai Patel, Himil Mahadevia, et al.
Targeted Oncology (2024) Vol. 19, Iss. 5, pp. 679-689
Closed Access | Times Cited: 1
Ahmed Elhariri, Jaydeepbhai Patel, Himil Mahadevia, et al.
Targeted Oncology (2024) Vol. 19, Iss. 5, pp. 679-689
Closed Access | Times Cited: 1
PDX models for functional precision oncology and discovery science
Zannel Blanchard, Elisabeth A. Brown, Arevik Ghazaryan, et al.
Nature reviews. Cancer (2024)
Closed Access | Times Cited: 1
Zannel Blanchard, Elisabeth A. Brown, Arevik Ghazaryan, et al.
Nature reviews. Cancer (2024)
Closed Access | Times Cited: 1
Molekulare Tumorboards
Johannes Jung, Linda Gräßel, Melanie Boerries, et al.
Forum (2024) Vol. 39, Iss. 1, pp. 33-37
Closed Access | Times Cited: 1
Johannes Jung, Linda Gräßel, Melanie Boerries, et al.
Forum (2024) Vol. 39, Iss. 1, pp. 33-37
Closed Access | Times Cited: 1
Data complexity in oncology
Péter Metzger, Linda Gräßel, Anna Lena Illert, et al.
Deleted Journal (2024) Vol. 30, Iss. 5, pp. 347-352
Open Access | Times Cited: 1
Péter Metzger, Linda Gräßel, Anna Lena Illert, et al.
Deleted Journal (2024) Vol. 30, Iss. 5, pp. 347-352
Open Access | Times Cited: 1
Tumor Copy Number Alteration Burden as a Predictor for Resistance to Immune Checkpoint Blockade across Different Cancer Types
Karama Asleh, Rodney J. Ouellette
Cancers (2024) Vol. 16, Iss. 4, pp. 732-732
Open Access | Times Cited: 1
Karama Asleh, Rodney J. Ouellette
Cancers (2024) Vol. 16, Iss. 4, pp. 732-732
Open Access | Times Cited: 1
Identifying Oncology Clinical Trial Candidates Using Artificial Intelligence Predictions of Treatment Change: A Pilot Implementation Study
Kenneth L. Kehl, Tali Mazor, Pavel Trukhanov, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 1
Kenneth L. Kehl, Tali Mazor, Pavel Trukhanov, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 1
Engineering Tumor Stroma Morphogenesis Using Dynamic Cell-Matrix Spheroid Assembly
Michael J. Buckenmeyer, Elizabeth Brooks, M. TAYLOR, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Michael J. Buckenmeyer, Elizabeth Brooks, M. TAYLOR, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Personalisierte Medizin in der Onkologie
Alisa M. Lörsch, Johannes Jung, Sebastian Lange, et al.
Deleted Journal (2024) Vol. 45, Iss. 3, pp. 180-189
Closed Access | Times Cited: 1
Alisa M. Lörsch, Johannes Jung, Sebastian Lange, et al.
Deleted Journal (2024) Vol. 45, Iss. 3, pp. 180-189
Closed Access | Times Cited: 1
Agnostic drug development revisited
Alberto Hernando‐Calvo, Alice Rossi, María Vieito, et al.
Cancer Treatment Reviews (2024) Vol. 128, pp. 102747-102747
Closed Access | Times Cited: 1
Alberto Hernando‐Calvo, Alice Rossi, María Vieito, et al.
Cancer Treatment Reviews (2024) Vol. 128, pp. 102747-102747
Closed Access | Times Cited: 1
